ADVENTRX Pharmaceuticals is a biopharmaceutical company engaged in the development of proprietary product candidates for treating various diseases and conditions. ANX-188, the company’s lead product candidate, is initially being developed as a treatment for complications arising from sickle cell disease and has the potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in various serious and life-threatening diseases and conditions. For more information, visit the company’s Web site at www.adventrx.com.

The 6th Annual OneMedForum is a gathering of leading investors and management of some of the most promising emerging life science companies in Asia and North America. Through panels, workshops and up-close programming with top industry leaders, attendees explore strategies for company growth finance with healthcare investors looking for outsized returns. For more information, please visit www.onemedforum.com.

Let us hear your thoughts below: